Cargando…

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment

Introduction: Schizophrenia is a serious mental illness that requires effective treatment with minimal adverse effects. As preclinical and clinical research progresses, trace amine-associated receptor 1 (TAAR1) is becoming a potential new target for the treatment of schizophrenia. Methods: We used m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yunjie, Liu, Zhaofeng, Lu, Jing, Wang, Wenyan, Wang, Lin, Yang, Yifei, Wang, Hongbo, Ye, Liang, Zhang, Jianzhao, Tian, Jingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160475/ https://www.ncbi.nlm.nih.gov/pubmed/37153799 http://dx.doi.org/10.3389/fphar.2023.1161964

Ejemplares similares

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
por: Heffernan, Michele L. R., et al.
Publicado: (2021)

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397
por: Espinoza, Stefano, et al.
Publicado: (2018)

Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist
por: Ye, Liang, et al.
Publicado: (2023)

TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
por: Liu, Jian-Feng, et al.
Publicado: (2018)

New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection
por: Bellusci, Lorenza, et al.
Publicado: (2017)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
por: Achtyes, Eric D., et al.
Publicado: (2023)

Behavioral Effects of a Potential Novel TAAR1 Antagonist
por: Lam, Vincent M., et al.
Publicado: (2018)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Investigation of Naturally Occurring Single-Nucleotide Variants in Human TAAR1
por: Mühlhaus, Jessica, et al.
Publicado: (2017)

The Case for TAAR1 as a Modulator of Central Nervous System Function
por: Rutigliano, Grazia, et al.
Publicado: (2018)

Review and Meta-Analyses of TAAR1 Expression in the Immune System and Cancers
por: Fleischer, Lisa M., et al.
Publicado: (2018)

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
por: Dedic, Nina, et al.
Publicado: (2021)

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia
por: Wang, Wenyan, et al.
Publicado: (2021)

Trace Amine Associated Receptor 1 (TAAR1) Modulation of Food Reward
por: Moore, Catherine F., et al.
Publicado: (2018)

Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
por: Xi, Lili, et al.
Publicado: (2023)

Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies
por: Francesconi, Valeria, et al.
Publicado: (2020)

Striatal Tyrosine Hydroxylase Is Stimulated via TAAR1 by 3-Iodothyronamine, But Not by Tyramine or β-Phenylethylamine
por: Zhang, Xiaoqun, et al.
Publicado: (2018)

Structural and Functional Evolution of the Trace Amine-Associated Receptors TAAR3, TAAR4 and TAAR5 in Primates
por: Stäubert, Claudia, et al.
Publicado: (2010)

TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP-363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

Study on Pharmacokinetics and Metabolic Profiles of Novel Potential PLK-1 Inhibitors by UHPLC-MS/MS Combined with UHPLC-Q-Orbitrap/HRMS
por: Wang, Lin, et al.
Publicado: (2023)

Correction To: TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT(1A) receptor agonist SEP- 363856
por: Saarinen, Marcus, et al.
Publicado: (2022)

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022)

Dynamic Stability of Volatile Organic Compounds in Respiratory Air in Schizophrenic Patients and Its Potential Predicting Efficacy of TAAR Agonists
por: Held, Anna, et al.
Publicado: (2023)

Canonical TSH Regulation of Cathepsin-Mediated Thyroglobulin Processing in the Thyroid Gland of Male Mice Requires Taar1 Expression
por: Qatato, Maria, et al.
Publicado: (2018)

Identification and characterization of cichlid TAAR genes and comparison with other teleost TAAR repertoires
por: Azzouzi, Naoual, et al.
Publicado: (2015)

In silico Docking Studies of Fingolimod and S1P(1) Agonists
por: Marciniak, Alexander, et al.
Publicado: (2020)

A Spontaneous Mutation in Taar1 Impacts Methamphetamine-Related Traits Exclusively in DBA/2 Mice from a Single Vendor
por: Reed, Cheryl, et al.
Publicado: (2018)

Discovery of Guanfacine as a Novel TAAR1 Agonist: A Combination Strategy through Molecular Modeling Studies and Biological Assays
por: Cichero, Elena, et al.
Publicado: (2023)

Search for Structural Basis of Interactions of Biogenic Amines with Human TAAR1 and TAAR6 Receptors
por: Glyakina, Anna V., et al.
Publicado: (2021)

Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
por: Zhu, Haibo, et al.
Publicado: (2021)

Analysis of Human TAAR8 and Murine Taar8b Mediated Signaling Pathways and Expression Profile
por: Mühlhaus, Jessica, et al.
Publicado: (2014)

Taare Zameen Par and dyslexic savants
por: Chakravarty, Ambar
Publicado: (2009)

CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist
por: Kevin, Richard C., et al.
Publicado: (2019)

Novel TRPV1 Channel Agonists With Faster and More Potent Analgesic Properties Than Capsaicin
por: Duarte, Yorley, et al.
Publicado: (2020)

Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans
por: Hopkins, Seth C., et al.
Publicado: (2021)

The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice
por: Ren, Xia, et al.
Publicado: (2022)

Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer
por: Li, Haobin, et al.
Publicado: (2022)

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
por: Ågren, Richard, et al.
Publicado: (2023)

Identification of Oleanolic Acid as Allosteric Agonist of Integrin α(M) by Combination of In Silico Modeling and In Vitro Analysis
por: Jin, Lu, et al.
Publicado: (2021)

The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties
por: Beattie, David T., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lda65s9q9nb8temiqn55m6nq6a